MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Incyte Corp

Închisă

SectorSănătate

68.58 1.25

Rezumat

Modificarea prețului

24h

Curent

Minim

67.48

Maxim

69.22

Indicatori cheie

By Trading Economics

Venit

-43M

158M

Vânzări

-126M

1.1B

P/E

Medie Sector

336.35

39.564

EPS

1.16

Marjă de profit

15.025

Angajați

2,617

EBITDA

-80M

257M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+13.68% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-2.8B

13B

Deschiderea anterioară

67.33

Închiderea anterioară

68.58

Sentimentul știrilor

By Acuity

30%

70%

68 / 376 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Incyte Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

9 iul. 2025, 15:46 UTC

Principalele dinamici ale pieței

BitMine Shares Fall After Closing of $250 Million Private Placement

9 iul. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 iul. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 iul. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 iul. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 iul. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 iul. 2025, 20:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iul. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iul. 2025, 20:26 UTC

Câștiguri

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 iul. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 iul. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 iul. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 iul. 2025, 17:07 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 iul. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 iul. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 iul. 2025, 16:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Health Care Roundup: Market Talk

9 iul. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 iul. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 iul. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 iul. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 iul. 2025, 16:14 UTC

Achiziții, Fuziuni, Preluări

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 iul. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 iul. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 iul. 2025, 15:31 UTC

Principalele dinamici ale pieței

BitMine Shares Fall After Closing of $250M Private Placement

9 iul. 2025, 15:31 UTC

Market Talk
Achiziții, Fuziuni, Preluări

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 iul. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 iul. 2025, 14:36 UTC

Achiziții, Fuziuni, Preluări

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 iul. 2025, 14:31 UTC

Achiziții, Fuziuni, Preluări

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 iul. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 iul. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparație

Modificare preț

Incyte Corp Așteptări

Obiectiv de preț

By TipRanks

13.68% sus

Prognoză pe 12 luni

Medie 76.93 USD  13.68%

Maxim 107 USD

Minim 52 USD

În baza a 17 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIncyte Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

17 ratings

7

Cumpărare

9

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

59.52 / 62.66Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

68 / 376 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation